Sanchez M L, Wenzel R P, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
Antimicrob Agents Chemother. 1992 Apr;36(4):873-5. doi: 10.1128/AAC.36.4.873.
The in vitro activity of decaplanin (formerly M86-1410), a novel glycopeptide antimicrobial agent, was tested against 169 gram-positive bloodstream isolates from patients at the University of Iowa Hospitals and Clinics and 12 selected vancomycin-resistant strains. Enterococcus faecalis, E. faecium, Staphylococcus aureus, streptococci, bacilli, corynebacteria, and listeria were inhibited by decaplanin (MICs for 90% of the strains tested [MIC90s], 0.12 to 4 micrograms/ml). However, some rarely isolated and selected Enterococcus sp. populations had a MIC90 of 16 micrograms/ml, and S. haemolyticus strains had a MIC90 of 8 micrograms/ml. These in vitro results suggest that decaplanin may be useful against most gram-positive strains, even though some Enterococcus species and coagulase-negative staphylococci were potentially resistant (MICs, greater than or equal to 8 micrograms/ml).
新型糖肽类抗菌药物去甲万古霉素（原名M86 - 1410）的体外活性，针对爱荷华大学医院和诊所患者的169株革兰氏阳性血流分离株以及12株选定的耐万古霉素菌株进行了测试。粪肠球菌、屎肠球菌、金黄色葡萄球菌、链球菌、芽孢杆菌、棒状杆菌和李斯特菌均被去甲万古霉素抑制（90%受试菌株的最低抑菌浓度[MIC90]为0.12至4微克/毫升）。然而，一些罕见分离和选定的肠球菌种群的MIC90为16微克/毫升，溶血葡萄球菌菌株的MIC90为8微克/毫升。这些体外结果表明，去甲万古霉素可能对大多数革兰氏阳性菌株有效，尽管一些肠球菌属和凝固酶阴性葡萄球菌可能具有耐药性（MIC大于或等于8微克/毫升）。
